OSAKA -- Japanese drugmaker Shionogi expects to be able to sell its Xocova COVID-19 treatment in the U.S. in early 2025, part of a focus on overseas sales as public funding for coronavirus medications in Japan ends this month.
Pharmaceuticals
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill
Drugmaker looks overseas for Xocova sales growth as public funds dry up at home
Shionogi President Isao Teshirogi said swift U.S. approval for Xocova would speed the process in other countries. (Photo by Keiichiro Sato)
Read Next
Latest on Pharmaceuticals
